logo
Plus   Neg
Share
Email

NVO : FDA Oks Ozempic For CV Risk Reduction In Type 2 Diabetes & Established CVD

Novo Nordisk said that the U.S. Food and Drug Administration has approved a label expansion based on a supplemental New Drug Application or sNDA for Ozempic for the indication of reducing the risk of major adverse cardiovascular events or MACE including cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes and established cardiovascular disease or CVD.

The approval was based on the SUSTAIN 6 cardiovascular outcomes trial (CVOT), which demonstrated that Ozempic statistically significantly reduced the risk of CV death, non-fatal heart attack or non-fatal stroke by 26% versus placebo, when added to standard of care in people with type 2 diabetes with increased CV risk.

The FDA also updated the Rybelsus label to include additional information from the PIONEER 6 CVOT demonstrating CV safety.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
McDonald's unveils Golden Shamrock Shake to commemorate the 50th anniversary of its Shamrock Shake. Six days after the return of the popular, mint-flavored shake, McDonald's Tuesday announced it is auctioning off a jewel-and-diamond-encrusted 18-karat gold cup, called the Golden Shamrock Shake, with... Walt Disney Co. (DIS) Tuesday announced CEO Robert Iger will step down immediately, and will be replaced by Bob Chapek. Chapek most recently served as Chairman of Disney Parks, Experiences and Products. Iger will assume the role of Executive Chairman and will "direct the company's creative endeavors,"... Shares of Salesforce.com Inc. (CRM) slipped nearly 3% in after-hours trading Tuesday. The cloud-based enterprise software marker reported a fourth-quarter profit that trumped Wall Street estimates as did its revenues. However, the company announced that its co-Chief Executive Keith Block is stepping...
Follow RTT
>